v3.26.1
Intangibles, Net and Goodwill
6 Months Ended
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Intangibles, Net and Goodwill
6. Intangibles, Net and Goodwill
Intangibles, Net
Finite-lived Intangible Assets
As of June 30, 2026, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D, the milestones paid to PARI Pharma GmbH (PARI) for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively, the milestone paid to AstraZeneca AB (AstraZeneca) as a result of the FDA approval of BRINSUPRI in August 2025, and the milestone paid to AstraZeneca as a result of the EC approval of BRINSUPRI in November 2025. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years, and began amortizing its AstraZeneca milestone-related intangible assets in August and November 2025 over BRINSUPRI's regulatory exclusivity period of approximately 14 years. Amortization expense is estimated to be $8.3 million per year for the years 2026 through 2029 and $7.1 million for 2030.
Indefinite-lived Intangible Assets
As of June 30, 2026, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition. Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the six months ended June 30, 2026 and 2025 is as follows (in thousands):
Intangible AssetDecember 31, 2025AdditionsAmortizationJune 30, 2026
Acquired ARIKAYCE R&D$23,038 $— $(2,425)$20,613 
PARI milestones962 — (101)861 
AstraZeneca milestones44,051 — (1,636)42,415 
Acquired IPR&D29,600 — — 29,600 
$97,651 $— $(4,162)$93,489 
Intangible AssetDecember 31, 2024AdditionsAmortizationJune 30, 2025
Acquired ARIKAYCE R&D$27,888 $— $(2,425)$25,463 
PARI milestones1,164 — (101)1,063 
Acquired IPR&D29,600 — — 29,600 
$58,652 $— $(2,526)$56,126 
Goodwill
The Company's goodwill balance of $136.1 million as of June 30, 2026 and December 31, 2025, resulted from the August 2021 Business Acquisition.